India, Jan. 15 -- Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Eltrombopag Tablets in strengths of 12.5 mg, 25 mg, 50 mg, and 75 mg. The reference listed drug is Promacta Tablets of corresponding strengths.
Eltrombopag tablets are indicated for the treatment of thrombocytopenia (low platelet count) associated with certain blood disorders. The drug works by stimulating bone marrow cells to increase platelet production, thereby lowering the risk of bleeding.
The tablets will be manufactured at the group's formulation facility located at the SEZ in Ahmedabad. In the United States, Eltrombopag tablets recorded annual sales of USD 1,262.5 million, according to IQVIA MAT ...